Glycated Albumin as a Novel Biomarker for Diabetes in Pregnancy: Current Status and Future Prospect

Siti Nurwani Ahmad Ridzuan, Karniza Khalid, Muhammad Nursyazwan Zamre, Nurul Izzati Hamzan, Ainna Mohd. Nor, Noor Hafizah Hassan, Anasufiza Habib


Glycemic biomarkers are important for diagnosis, monitoring, treatment, and prognostication of diabetes complications. In this rapid review, we focus on the strengths and limitation of selected glycemic biomarkers for monitoring purposes in pregnancy: Hemoglobin A1C, fructosamine, and glycated albumin (GA). We elaborated on the characteristics of each marker, the similarities, and differences. We summarize the review with important evidence on the utility and future prospect of GA beyond glycemic monitoring. In summary, GA is a good tool to address the inherent limitation of A1C as a glycemic biomarker. The elucidation provided in this review is poised to enhance the pragmatic and clinical applicability of various glycemic biomarkers in different settings in routine clinical practice


biomarker, glycated albumin, pregnancy, diabetes mellitus, monitoring

Full Text:



A. Ornoy, M. Becker, L. Weinstein-Fudim, and Z. Ergaz, “Diabetes during pregnancy: A maternal disease complicating the course of pregnancy with long-term deleterious effects on the offspring. a clinical review,” International Journal of Molecular Sciences, vol. 22, no. 6. Multidisciplinary Digital Publishing Institute, pp. 1–38, 15-Mar-2021.

M. I. Maiorino et al., “Effects of continuous glucose monitoringonmetricsofglycemic control in diabetes: A Systematic Review with Meta-analysis of Randomized Controlled Trials,” Diabetes Care, vol. 43, no. 5. American Diabetes Association, pp. 1146–1156, 01-May-2020.

T. Wada et al., “Progesterone inhibits glucose uptake by affecting diverse steps of insulin signaling in 3T3-L1 adipocytes,” Am. J. Physiol. - Endocrinol. Metab., vol. 298, no. 4, pp. 881–888, Apr. 2010.

F. Y. Kuo, K.-C. Cheng, Y. Li, and J.-T. Cheng, “Oral glucose tolerance test in diabetes, the old method revisited,” World J. Diabetes, vol. 12, no. 6, pp. 786–793, Jun. 2021.

H. Chehregosha, M. E. Khamseh, M. Malek, F. Hosseinpanah, and F. Ismail-Beigi, “A View Beyond HbA1c: Role of Continuous Glucose Monitoring,” Diabetes Therapy, vol. 10, no. 3. Springer Healthcare, pp. 853–863, 01-Jun-2019.

V. N. Shah et al., “Relationship between Time-in-Range, HbA1c, and the Glucose Management Indicator in Pregnancies Complicated by Type 1 Diabetes,” Diabetes Technol. Ther., vol. 23, no. 12, pp. 783–790, Nov. 2021.

L. Raets, K. Beunen, and K. Benhalima, “Screening for gestational diabetes mellitus in early pregnancy: What is the evidence?,” Journal of Clinical Medicine, vol. 10, no. 6. Multidisciplinary Digital Publishing Institute, pp. 1–16, 18-Mar-2021.

M. Lemaitre, C. Ternynck, J. Bourry, F. Baudoux, D. Subtil, and A. Vambergue, “Association Between HbA1c Levels on Adverse Pregnancy Outcomes During Pregnancy in Patients With Type 1 Diabetes,” J. Clin. Endocrinol. Metab., vol. 107, no. 3, pp. E1117–E1125, Feb. 2022.

N. Furusyo and J. Hayashi, “Glycated albumin and diabetes mellitus,” Biochimica et Biophysica Acta - General Subjects, vol. 1830, no. 12. Elsevier, pp. 5509–5514, 01-Dec-2013.

F. C. Chume, P. B. Renz, M. K. Hernandez, P. A. C. Freitas, and J.

L. Camargo, “Is there a role for glycated albumin in the diagnosis of gestational diabetes mellitus?,” Endocrine, vol. 72, no. 3, pp. 681–687, Jun. 2021.

X. Liu, N. Wu, and A. Al-Mureish, “A review on research progress in the application of glycosylated hemoglobin and glycated albumin in the screening and monitoring of gestational diabetes,” International Journal of General Medicine, vol. 14. Dove Medical Press Ltd, pp. 1155–1165, 2021.

T. Kohzuma, X. Tao, and M. Koga, “Glycated albumin as biomarker: Evidence and its outcomes,” J. Diabetes Complications, vol. 35, no. 11, p. 108040, Nov. 2021.

M. Zendjabil, “Glycated albumin,” Clinica Chimica Acta, vol. 502. Elsevier, pp. 240–244, 01-Mar-2020.

K. Hashimoto, “Indicators of glycemic control in patients with gestational diabetes mellitus and pregnant women with diabetes mellitus,” World J. Diabetes, vol. 6, no. 8, p. 1045, Jul. 2015.

A. Sweeting, J. Wong, H. R. Murphy, and G. P. Ross, “A Clinical Update on Gestational Diabetes Mellitus,” Endocrine Reviews, vol. 43, no. 5. Oxford Academic, pp. 763–793, 26-Sep-2022.

S. Suehara, M. Waguri, K. Wakabayashi, and I. Nakanishi, “Frequency and congenital anomaly of pregnant women with diabetes mellitus and gestational diabetes mellitus,” Diabetes and Pregnancy, vol. 10, pp. 104–108, 2010.

Y. Saisho et al., “Beta cell dysfunction and its clinical significance in gestational diabetes,” Endocr. J., vol. 57, no. 11, pp. 973–980, 2010.

S. Knapp, “Diabetes and infection: Is there a link? - A mini-review,” Gerontology, vol. 59, no. 2. S. Karger AG, pp. 99–104, 01-Feb-2013.

E. Danese, M. Montagnana, A. Nouvenne, and G. Lippi, “Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes,” in Journal of Diabetes Science and Technology, 2015, vol. 9, no. 2, pp. 169–176.

E. Danese, M. Montagnana, A. Nouvenne, and G. Lippi, “Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes,” in Journal of Diabetes Science and Technology, 2015, vol. 9, no. 2, pp. 169–176.

V. Gounden, M. Ngu, C. Anastasopoulou, and I. Jialal, “Fructosamine,” StatPearls, Aug. 2023.

M. M. Agarwal, G. S. Dhatt, Y. Othman, and M. R. Ljubisavljevic, “Gestational diabetes: An evaluation of serum fructosamine as a screening test in a high-risk population,” Gynecol. Obstet. Invest., vol. 71, no. 3, pp. 207–212, Apr. 2011.

A. Ekhzaimy et al., “Fructosamine as an Index of Short-Term Glycemic Control in Pregnant Women with Diabetes: Before, During and After Ramadan,” Int. J. Womens. Health, vol. 14, pp. 435–444, 2022.

E. Bernier et al., “Trimester-Specific Serum Fructosamine in Association with Abdominal Adiposity, Insulin Resistance, and Inflammation in Healthy Pregnant Individuals,” Nutrients, vol. 14, no. 19, p. 3999, Oct. 2022.

V. Gingras, S. L. Rifas-Shiman, K. M. Switkowski, E. Oken, and M. F. Hivert, “Mid-pregnancy fructosamine measurement—Predictive value for gestational diabetes and association with postpartum glycemic indices,” Nutrients, vol. 10, no. 12, p. 2003, Dec. 2018.

S. Ayyappan, S. Philips, C. K. Kumar, V. Vaithiyanandane, and C. Sasikala, “Serum fructosamine a better indicator than glycated hemoglobin for monitoring gestational diabetes mellitus,” J. Pharm. Bioallied Sci., vol. 7, no. Suppl 1, pp. S32–S34, Apr. 2015.

T. A. Pramodkumar et al., “1,5 Anhydroglucitol in gestational diabetes mellitus,” J. Diabetes Complications, vol. 33, no. 3, pp. 231–235, Mar. 2019.

T. Ninomiya, “Diabetes mellitus and dementia,” Current Diabetes Reports, vol. 14, no. 5. Current Medicine Group LLC 1, pp. 1–9, 13-Mar-2014.

T. Ohara et al., “Glucose tolerance status and risk of dementia in the community: The Hisayama Study,” Neurology, vol. 77, no. 12, pp. 1126–1134, Sep. 2011.

A. M. Rawling

s et al., “The association of late-life diabetes status and hyperglycemia with incident mild cognitive impairment and dementia: The ARIC study,” Diabetes Care, vol. 42, no. 7, pp. 1248–1264, Jul. 2019.

N. Mukai et al., “Alternative measures of hyperglycemia and risk of Alzheimer’s disease in the community: The hisayama study,” J. Clin. Endocrinol. Metab., vol. 102, no. 8, pp. 3002–3010, Aug. 2017.

T. Ohara et al., “Elevated serum glycated albumin and glycated albumin : hemoglobin A1c ratio were associated with hippocampal atrophy in a general elderly population of Japanese: The Hisayama Study,” J. Diabetes Investig., vol. 11, no. 4, pp. 971–979, Jul. 2020.

A. Hidaka et al., “Plasma C-peptide and glycated albumin and subsequent risk of cancer: From a large prospective case-cohort study in Japan,” Int. J. Cancer, vol. 144, no. 4, pp. 718–729, Feb. 2019.

K. Ozasa et al., “Glucose intolerance and colorectal cancer risk in a nested case-control study among Japanese people,” J. Epidemiol., vol. 15, no. SUPPL. 2, pp. S180–S184, 2005.

M. T. Marrone, E. Selvin, J. R. Barber, E. A. Platz, and C. E. Joshu, “Hyperglycemia, classified with multiple biomarkers simultaneously in men without diabetes, and risk of fatal prostate cancer,” Cancer Prev. Res., vol. 12, no. 2, pp. 103–112, Feb. 2019.

Copyright (c) 2024 Journal of Biomedical and Clinical Sciences (JBCS)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.


Flag Counter           


                                              Copyright © 2016 AMDI Publisher, Universiti Sains Malaysia.
Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Sains Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
                                            Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.